Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of HRS-1780 in Healthy Males
NCT05638126Phase 1Unknown
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-1780 in chronic kidney disease (CKD) (3 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoint: Incidence and severity of adverse events at 1 month. Status: unknown.
02
Drugs
HRS-1780
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05638126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638126.